Microglial inflammatory signaling

Microglial inflammatory signaling is a complex biological process involving the activation of the central nervous system's resident immune cells in response to pathological stimuli [1.1.1]. This signaling is initiated by the recognition of damage-associated molecular patterns (DAMPs) or pathogens by various surface receptors, including Toll-like receptor 4 (TLR4), TREM2, and P2X7 [1.1.2, 1.3.3]. Upon activation, microglia trigger intracellular cascades such as the NF-κB, MAPK, and JAK/STAT pathways, leading to the assembly of the NLRP3 inflammasome and the subsequent release of pro-inflammatory cytokines like IL-1β, TNF-α, and IL-6 [1.2.1, 1.3.1]. While acute signaling is essential for debris clearance and injury resolution, chronic or dysregulated microglial inflammatory signaling is a primary driver of neuroinflammation in neurodegenerative diseases like Alzheimer's and Parkinson's, as well as in psychiatric conditions like depression [1.1.5, 1.2.1]. Therapeutic interventions target various nodes of this signaling network, including receptor antagonists (e.g., TAK-242), inflammasome inhibitors (e.g., MCC950), and modulators of microglial polarization, to mitigate neurotoxicity and preserve neuronal health [1.1.2, 1.2.3].

Other names

Microglial activationMicroglial neuroinflammatory cascadeMicroglial pro-inflammatory signalingM1 microglial polarization

Therapeutic modulation involves the inhibition of pro-inflammatory receptors (e.g., TLR4, P2X7), the suppression of intracellular signaling nodes (e.g., NF-κB, JAK/STAT), or the activation of homeostatic receptors (e.g., TREM2) to shift microglia from a neurotoxic to a neuroprotective state [1.1.2, 1.2.3, 1.3.1].